Purchase this article with an account.
Juan E. Gallo, Jorge E. Mancini, Juan O. Croxatto; Suramin and PPADS Downregulate Proinflammatory Citokines in the Retina of a Rat Model of Type 1 Diabetes. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3285.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the expression of TNF-a, IL-17, c-PLA2, GFAP and P2X2 in the retina of type 1 diabetic rat treated with PPADS and Suramin
Sixteen male Wistar rats of 250gr were treated with an intraperitoneal injection of 45mg/kg of streptozotocin. Only animals with glycemia levels above 200mg/dl were included in the study. The treated animals were divided into three groups of 4 rats. These were intraperitoneally injected with: 1) Suramin, 2) PPADS, 3) Suramin + PPADS at 9 and 26 weeks of diabetes in each group. Four remaining diabetic animals received no treatment. Twelve non-diabetic rats with the same age of diabetics were used as a control group. Animals were sacrificed after 38 weeks of diabetes. Cross sections of retinas were analyzed by immunohistochemistry using primary antibodies against GFAP, TNF-alfa, IL-17, cPLA2 and P2X2 receptor.
Immunostaining of the analyzed antibodies were clearly up-regulated in diabetic animals without treatment. Diabetic rats treated with Suramin, PPADS and the combined compound showed up a pattern and immunostaining similar to that seen in the control group. Staining was much lower in animals treated with suramin than that found in those treated with PPADS
Suramin and PPADS may be good therapeutical candidates for the treatment of diabetic retinopathy during the inflammatory stage of the disease. Further studies are being conducted.
This PDF is available to Subscribers Only